Published in Vaccine on August 01, 1994
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad) | NCT01082341
Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol (2006) 2.97
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell (2014) 2.23
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe (2014) 1.57
Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis (2011) 1.54
Age-Related Changes in Human Peripheral Blood IGH Repertoire Following Vaccination. Front Immunol (2012) 1.39
Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods (2008) 1.28
Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol (2012) 1.14
Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis (2010) 1.12
Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother (2013) 1.12
Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods (2010) 1.09
Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol (2012) 1.08
Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol (2014) 1.02
Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J Immunol (2011) 0.99
Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol (2007) 0.95
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel) (2015) 0.93
Antibody detection and kinetics of antibody production during early stages of immunization with hepatitis B virus vaccine. Clin Vaccine Immunol (2007) 0.89
Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial. Hum Vaccin Immunother (2013) 0.87
Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol (2015) 0.86
Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine (2012) 0.85
The human side of influenza. J Leukoc Biol (2012) 0.83
Persistence of diarrheal pathogens is associated with continued recruitment of plasmablasts in the circulation. Clin Dev Immunol (2012) 0.83
Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int J Med Sci (2011) 0.83
New approaches to understanding the immune response to vaccination and infection. Vaccine (2015) 0.82
Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. Virol J (2009) 0.82
Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015). Hum Vaccin Immunother (2015) 0.81
Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respir Viruses (2007) 0.80
Early detection of human immunodeficiency virus type 1-specific B-lymphocyte-derived antibodies in a high-risk population. Clin Vaccine Immunol (2009) 0.79
The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine (2016) 0.78
The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum Vaccin Immunother (2012) 0.78
Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. Front Immunol (2014) 0.77
Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. Int J Chron Obstruct Pulmon Dis (2007) 0.77
Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum Vaccin Immunother (2015) 0.76
Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils. J Infect Dis (2016) 0.75
Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets. PLoS One (2015) 0.75
Proteomic contributions to our understanding of vaccine and immune responses. Proteomics Clin Appl (2015) 0.75
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. J Immunol (2017) 0.75
Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk. PLoS One (2014) 0.75
The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine. Hum Vaccin Immunother (2015) 0.75
Effectiveness of seasonal influenza vaccination in patients with diabetes: protocol for a nested case-control study. BMJ Open (2017) 0.75
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Determinants of immunity to influenza infection in man. Br Med Bull (1979) 4.62
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38
Evidence for host-cell selection of influenza virus antigenic variants. Nature (1983) 4.24
Synthesis of methyl-mercury compounds by extracts of a methanogenic bacterium. Nature (1968) 4.01
Gene products that promote mRNA turnover in Saccharomyces cerevisiae. Mol Cell Biol (1992) 4.00
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res (2004) 3.95
Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 3.81
Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol (2003) 3.23
Predictors of future falls in Parkinson disease. Neurology (2010) 3.00
Immunity to influenza in ferrets. I. Response to live and killed virus. Br J Exp Pathol (1972) 2.78
Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: potential role of defective interfering RNAs in nature. J Virol (1985) 2.75
Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis (1995) 2.67
Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet (1969) 2.66
Biological cycles for toxic elements in the environment. Science (1974) 2.62
Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology (1987) 2.58
An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand (1977) 2.46
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol (2000) 2.41
The metabolism of protocatechuate by Pseudomonas testosteroni. Biochem J (1968) 2.41
VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci (2000) 2.38
Genetics of L-proline utilization in Escherichia coli. J Bacteriol (1981) 2.37
The degradation of trans-ferulic acid by Pseudomonas acidovorans. Biochemistry (1970) 2.29
Proline transport and osmotic stress response in Escherichia coli K-12. J Bacteriol (1986) 2.29
Symbiotic properties of C4-dicarboxylic acid transport mutants of Rhizobium leguminosarum. J Bacteriol (1983) 2.19
Circulation of influenza viruses and paramyxoviruses in waterfowl originating from two different areas of North America. Bull World Health Organ (1985) 2.18
Oxybenzone oxidation following solar irradiation of skin: photoprotection versus antioxidant inactivation. J Invest Dermatol (1996) 2.07
Succinate transport in Rhizobium leguminosarum. J Bacteriol (1981) 2.04
Leucine transport in Escherichia coli. The resolution of multiple transport systems and their coupling to metabolic energy. J Biol Chem (1975) 2.02
Hepatitis B transmission from contaminated cryopreservation tank. Lancet (1995) 1.99
The polymerisation of dietary sugars by dental plaque. Caries Res (1967) 1.96
Proline porter II is activated by a hyperosmotic shift in both whole cells and membrane vesicles of Escherichia coli K12. J Biol Chem (1988) 1.95
Isolation and sequencing of Escherichia coli gene proP reveals unusual structural features of the osmoregulatory proline/betaine transporter, ProP. J Mol Biol (1993) 1.94
The reaction of multihalogenated hydrocarbons with free and bound reduced vitamin B 12. Biochemistry (1968) 1.93
Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol (1991) 1.89
Mechanical properties of vesicles. II. A model for osmotic swelling and lysis. Biophys J (1993) 1.89
Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG (2000) 1.88
Biomethylation of toxic elements in the environment. Science (1977) 1.87
Formation of methane from serine by cell-free extracts of Methanobacillus omelianskii. J Biol Chem (1965) 1.85
The extracellular polysaccharide produced from sucrose by a cariogenic streptococcus. Arch Oral Biol (1966) 1.83
Biochemistry and regulation of a second L-proline transport system in Salmonella typhimurium. J Bacteriol (1980) 1.77
Simian virus 40-induced T and tumor antigens. J Virol (1969) 1.76
Cimetidine and placebo in the treatment of benign gastric ulcer: a multicenter double blind study. Gastroenterology (1978) 1.75
Osmoadaptation by rhizosphere bacteria. Annu Rev Microbiol (1996) 1.74
Two proline porters in Escherichia coli K-12. J Bacteriol (1983) 1.70
Antigenic variation in current influenza A viruses: evidence for a high frequency of antigenic 'drift' for the Hong Kong virus. Bull World Health Organ (1974) 1.68
The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol Cell Biol (1994) 1.67
Immunological and physicochemical studies of influenza matrix (M) polypeptides. Virology (1976) 1.66
The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. J Hyg (Lond) (1979) 1.65
Kinetic and Mössbauer studies on the mechanism of protocatechuic acid 4,5-oxygenase. Biochemistry (1972) 1.64
Characterization of an inducible porter required for L-proline catabolism by Escherichia coli K12. Can J Biochem (1979) 1.60
Redesigned purification yields a fully functional PutA protein dimer from Escherichia coli. J Biol Chem (1992) 1.60
The next influenza pandemic: lessons from Hong Kong, 1997. Emerg Infect Dis (1999) 1.58
In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc (1999) 1.58
How do children tell? The disclosure process in child sexual abuse. Child Abuse Negl (1996) 1.55
Sequence analysis identifies the proline dehydrogenase and delta 1-pyrroline-5-carboxylate dehydrogenase domains of the multifunctional Escherichia coli PutA protein. J Mol Biol (1994) 1.52
Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J Gen Virol (1975) 1.51
Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology (1995) 1.51
Proline dehydrogenase from Escherichia coli K12. Properties of the membrane-associated enzyme. Eur J Biochem (1983) 1.50
Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2 -Hong Kong infection. A controlled double-blind study. Lancet (1971) 1.49
Na+ (Li+)-proline cotransport in Escherichia coli. J Membr Biol (1985) 1.48
Reactogenicity and immunogenicity of inactivated influenza A (H1N1) virus vaccine in unprimed children. Report to the Medical Research Council Committee on influenza and other respiratory virus vaccines. J Biol Stand (1980) 1.48
Membrane association of proline dehydrogenase in Escherichia coli is redox dependent. Proc Natl Acad Sci U S A (1987) 1.48
Studies on the mechanism of influenza virus entry into cells. J Gen Virol (1979) 1.46
Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand (1979) 1.45
Amplification of the put genes and identification of the put gene products in Escherichia coli K12. Can J Biochem (1980) 1.45
Evidence for antigenic variation in influenza A nucleoprotein. Virology (1979) 1.43
A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ (1975) 1.40
Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology (1993) 1.39
Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull World Health Organ (1969) 1.38
Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol (2000) 1.37
Changes in the antibody status of a population following epidemic infection by influenza virus A2-Hong Kong-1-68. J Hyg (Lond) (1970) 1.37
Immunofluorescent studies on the inhibition of influenza A and B viruses in mammalian cell cultures by amines and ammonium compounds. J Gen Virol (1968) 1.37
More than suggestion: the effect of interviewing techniques from the McMartin Preschool case. J Appl Psychol (1998) 1.35
The intracellular distribution of influenza virus matrix protein and nucleoprotein in infected cells and their relationship to haemagglutinin in the plasma membrane. J Gen Virol (1988) 1.35
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol (1999) 1.34
Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers. J Infect Dis (1978) 1.33
Biodegradation of natural and man-made recalcitrant compounds with particular reference to lignin. J Agric Food Chem (1977) 1.33
Conformational change and membrane association of the PutA protein are coincident with reduction of its FAD cofactor by proline. J Biol Chem (1993) 1.32
Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature (1977) 1.30
Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol (2005) 1.28
Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology (1994) 1.28
Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis (1995) 1.27
Serial examination of the normal visual field using Octopus automated projection perimetry. Evidence for a learning effect. Acta Ophthalmol (Copenh) (1987) 1.26
Mechanical properties of vesicles. I. Coordinated analysis of osmotic swelling and lysis. Biophys J (1993) 1.26
Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis. J Hyg (Lond) (1982) 1.25
In vivo selection of an influenza A2 strain resistant to amantadine. Nature (1970) 1.24
Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond. J Med Chem (1989) 1.24
Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis (1998) 1.24
Factors reducing and promoting the effectiveness of proline as an osmoprotectant in Escherichia coli K12. J Gen Microbiol (1987) 1.23
Vistech VCTS 6500 charts--within- and between-session reliability. Optom Vis Sci (1991) 1.21
Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacol Ther (1980) 1.21
Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology (1989) 1.20
Strain-specificity of antibody to haemagglutinin following inactivated A/port chalmers/1/73 vaccine in man: evidence for a paradoxical strain-specific antibody response. Dev Biol Stand (1978) 1.20
Mechanisms for the biomethylation of metals and metalloids. Fed Proc (1978) 1.19
Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. J Hyg (Lond) (1983) 1.19
The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology (1990) 1.19
Purification and reconstitution of an osmosensor: transporter ProP of Escherichia coli senses and responds to osmotic shifts. Biochemistry (1999) 1.18
Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. J Med Virol (1991) 1.18